This inventor holds 1 USPTO granted patent. Top assignee: Sterngreene, Inc.. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Innovations of Yingjie Cui in Cancer Treatment
Introduction
Yingjie Cui is a notable inventor based in Shanghai, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. His work focuses on creating effective solutions for patients facing challenges with existing treatments.
Latest Patents
Yingjie Cui holds a patent for pyrimidine compounds that are useful as tyrosine kinase inhibitors. This patent specifically addresses epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors. The disclosed EGFR inhibitors are particularly effective against acquired resistance mutations that can occur after treatment with existing EGFR inhibitors. Additionally, the patent outlines methods for treating cancer using these pyrimidine compounds and pharmaceutical compositions that include them. These methods are directed towards cancers that exhibit acquired resistance mutations.
Career Highlights
Yingjie Cui is associated with Sterngreene, Inc., where he continues to advance his research in the pharmaceutical field. His work has garnered attention for its potential to improve cancer treatment outcomes for patients who have developed resistance to current therapies.
Collaborations
Yingjie Cui collaborates with esteemed colleagues, including Lihu Yang and Guangning Ma. Their combined expertise contributes to the innovative research being conducted at Sterngreene, Inc.
Conclusion
Yingjie Cui's contributions to cancer treatment through his innovative patent on pyrimidine compounds highlight the importance of ongoing research in overcoming treatment resistance. His work represents a significant step forward in the fight against cancer.